Navigation Links
Einstein receives high-risk/high-reward cancer research funding
Date:12/7/2009

December 7, 2009 (BRONX, NY) Matthew Levy, Ph.D., assistant professor of biochemistry at Albert Einstein College of Medicine of Yeshiva University, has been awarded more than $700,000 by Stand Up To Cancer (SU2C) for his high-risk/high-reward cancer research. Dr. Levy's work will focus on creating self-guiding drugs that target only cancer cells, thus eliminating or significantly reducing serious or unpleasant side effects of current therapies. Dr. Levy is one of 13 young scientists nationwide selected to receive a total of $9.68 million through SU2C's Innovative Research Grant program, which supports the next generation of cancer research leaders.

"The Stand Up To Cancer Innovative Research Grant program is giving us the chance to test out our ideas on how to make current drugs better," said Dr. Levy. "In the end, our hope is that this will translate to more effective treatments and an increased quality of life for patients."

SU2C's funding model for the Innovative Research Grants was designed specifically to support work that utilizes new ideas and new approaches to solve critical problems in cancer research. These innovative projects are characterized as "high-risk" because they challenge existing paradigms and because, in order to receive a grant, the applicants were not required to have already conducted a portion of the research resulting in an established base of evidence. Most conventional funding mechanisms require such evidence upfront. If successful, these projects have the potential for "high-reward" in terms of saving lives.

Dr. Levy's research will focus on creating a new type of targeted therapeutic agent to treat cancers. Current chemotherapies capable of killing rapidly dividing cancer cells also kill normal, healthy cells, leading to undesirable side effects. Thirty-seven-year-old Dr. Levy proposes to tackle this challenge by developing a new type of compound that can selectively identify, bind to, and destroy
'/>"/>

Contact: Deirdre Branley
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Einstein to develop anti-HIV drug delivery system
2. Einstein scientists move closer to a safer anthrax vaccine
3. Einstein researchers devise a fast and sensitive way to detect ricin
4. NIH funds research center for womens reproductive health at Einstein
5. Einstein and Pitt researchers develop new TB test that will dramatically cut diagnosis time
6. Empire State Stem Cell Board awards $12.7 million to Albert Einstein College of Medicine
7. Einstein scientists receive $10 million NIH grant
8. Einstein researchers develop technique to count messages made by single genes
9. Einstein researchers develop a new way to study how breast cancer spreads
10. In scientific first, Einstein researchers correct decline in organ function associated with old age
11. Feinstein researchers develop new genetic method and identify novel genes for schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... arrhythmia a chronic irregularity of heartbeat which ... the condition is not acutely life-threatening, it does increase ... cardiac insufficiency, stroke and dementia. In the third of ... of researchers, led by LMU physician PD Dr. Stefan ...
... SAN DIEGO - Some say the world,s population will ... will present significant challenges for agriculture to provide enough ... scientist Rod Hill., Hill and Larry Branen, a University ... American Association for the Advancement of Science annual meeting ...
... hunger could be large over the next 20 years, according ... temperatures could significantly reduce yields of wheat, rice and maize ... who subsist on less than $1 a day. The resulting ... drive many into poverty. But even as some people ...
Cached Biology News:When the heart gets out of step 2When the heart gets out of step 3Biotech, nanotech and synthetic biology roles in future food supply explored 2Global warming may hurt some poor populations, benefit others 2Global warming may hurt some poor populations, benefit others 3Global warming may hurt some poor populations, benefit others 4
(Date:8/27/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, ... Company Limited (Biohaven), announced today that dosing has ... a glutamate modulating agent. Biohaven filed an investigational ... clearance from the U.S. Food and Drug Administration ... 54% equity interest in Biohaven, a private company. ...
(Date:8/27/2015)... , Aug. 27, 2015 HUYA Bioscience ... meeting of the Japan Society of HTLV-1, held this ... Auditorium. The purpose of the Society is to promote ... the development of medical technology and research related to ... welfare. "HUYA is proud to support this ...
(Date:8/27/2015)... , Aug. 27, 2015 In response ... FedEx, UPS and The US Postal Service to ... classified as ,select agents, by the CDC, Marken ... handling these sensitive shipments. Marken uses ... regulations, trained and certified personnel to ensure the ...
(Date:8/26/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, today announced that ... & Company Emerging Growth Conference on September 2 at ... New York Marriott Marquis. A live ... investor relations section of Roka Bioscience,s website at ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... DIEGO, Aug. 24, 2011 Biocept, Inc., a privately-held ... analysis of circulating tumor cells (CTCs) in cancer patients, ... a collaboration on the commercialization of a proprietary blood ... the determination of HER2 status.  Clarient and Biocept will ...
... PARIS and MINNEAPOLIS, Aug. 24, 2011 Cellectis ... subsidiary of Cellectis (Alternext: ALCLS), and Recombinetics, a ... entered a development and license agreement on the ... creates, in accordance with biosafety and animal well-being ...
... United Therapeutics Corporation (NASDAQ: UTHR ... Phase 3 trial of treprostinil diethanolamine (oral treprostinil), ... a stable synthetic form of prostacyclin, in patients ... that the trial did not achieve statistical significance ...
Cached Biology Technology:Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients 2Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients 3Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients 4Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 2Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 3FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 2FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 3FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 4
E2F2 protein...
Anti-DDDDK-Tag (Enterokinase Cleavage Site), Agarose Conjugate Research Focus: tag Storage: 4C Shipping Temperature: 4C...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Biology Products: